Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

By M. Cristofanilli, G. Budd, M. Ellis, A. Stopeck, J. Matera, M. Miller, J. Reuben, G. Doyle, W. Allard, L. Terstappen and 1 more. New England Journal of Medicine, 2004

4,418 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/8854d22a629bf5aee0383aa7df702091a81379e8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Aleix Prat
2. L. Terstappen
3. G. Doyle
4. M. Miller
5. Charles M. Perou
6. K. Yeung
7. Jing Yang
8. H. Horlings

In Oncology

1. G. Doyle
2. Jing Yang
3. M. Miller
4. L. Terstappen
5. Aleix Prat
6. K. Yeung
7. J. D. de Bono
8. Larry Norton

In Pulmonary and Respiratory Medicine

1. L. Sequist
2. Hans Lilja
3. M. Gijs
4. H. Horlings
5. C. Sawyers

Citations in the corpus

• Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer (2009, background): “In both univariate and multivariate analysis CTC levels at all time points were significantly associated with overall survival [10, 13, 15].”
• Liquid biopsy: current technology and clinical applications (2022, background): “5 ml of whole blood prior to treatment was an independent predictor of shorter progression-free and overall survival [82].”
• Circulating tumor cells: approaches to isolation and characterization (2011, background): “In patients with metastatic breast cancer, CTC counts above five CTCs per 7.5 ml of blood before the start of systemic therapy were associated with a shorter median progression-free survival and overall survival (Cristofanilli et al., 2004, 2008; Botteri et al., 2010).”
• Label-free cell separation and sorting in microfluidic systems (2010, methodology): “The commercially available CellSearch system (Veridex, LLC) has been used for continuous monitoring of CTCs from whole blood in patients with metastatic cancers [5].”
• Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer (2008, background): “cancer, and from our own preliminary modeling data (8, 9).”
• Small but Perfectly Formed? Successes, Challenges, and Opportunities for Microfluidics in the Chemical and Biological Sciences (2017, background): “5 mL).(37) Second, size- or inertial-based separation systems have a key advantage; they do not rely on affinity.”